CN116096377B - 跨物种相容的腺相关病毒组合物及其使用方法 - Google Patents

跨物种相容的腺相关病毒组合物及其使用方法

Info

Publication number
CN116096377B
CN116096377B CN202180044147.9A CN202180044147A CN116096377B CN 116096377 B CN116096377 B CN 116096377B CN 202180044147 A CN202180044147 A CN 202180044147A CN 116096377 B CN116096377 B CN 116096377B
Authority
CN
China
Prior art keywords
aav
vector
capsid protein
amino acid
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180044147.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116096377A (zh
Inventor
A·阿索坎
T·冈萨雷斯
L·P·哈利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN116096377A publication Critical patent/CN116096377A/zh
Application granted granted Critical
Publication of CN116096377B publication Critical patent/CN116096377B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180044147.9A 2020-05-05 2021-05-05 跨物种相容的腺相关病毒组合物及其使用方法 Active CN116096377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05
US63/020,062 2020-05-05
PCT/US2021/030937 WO2021226267A2 (en) 2020-05-05 2021-05-05 Cross-species compatible adeno-associated virus compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN116096377A CN116096377A (zh) 2023-05-09
CN116096377B true CN116096377B (zh) 2026-01-02

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044147.9A Active CN116096377B (zh) 2020-05-05 2021-05-05 跨物种相容的腺相关病毒组合物及其使用方法

Country Status (13)

Country Link
US (3) US12577586B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125977A4 (cg-RX-API-DMAC7.html)
JP (1) JP7756439B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230029616A (cg-RX-API-DMAC7.html)
CN (1) CN116096377B (cg-RX-API-DMAC7.html)
AR (1) AR122013A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021268946A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022644A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177869A1 (cg-RX-API-DMAC7.html)
IL (1) IL297577A (cg-RX-API-DMAC7.html)
MX (1) MX2022013963A (cg-RX-API-DMAC7.html)
TW (1) TWI910162B (cg-RX-API-DMAC7.html)
WO (1) WO2021226267A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910162B (zh) * 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2024044725A2 (en) * 2022-08-24 2024-02-29 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024168089A2 (en) * 2023-02-07 2024-08-15 Duke University Compositions comprising aavs and methods for treating gastrointestinal diseases
US20240261438A1 (en) * 2023-02-08 2024-08-08 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
EP4689139A1 (en) * 2023-03-31 2026-02-11 Duke University Compositions comprising brain-tropic aavs and methods of use thereof
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528916A (zh) * 2006-04-28 2009-09-09 宾夕法尼亚州立大学托管会 规模可调的aav生产方法
CN110520536A (zh) * 2017-02-15 2019-11-29 北卡罗来纳-查佩尔山大学 用于穿过维管结构的基因转移的方法和组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
US11136557B2 (en) * 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
JP2020510424A (ja) 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 改変aavカプシドおよびその使用
GB2574561A (en) 2017-03-14 2019-12-11 Univ California Engineering CRISPR CAS9 immune stealth
WO2018170310A1 (en) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2020010465A (es) * 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
EP3860659A1 (en) * 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
TWI910162B (zh) 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528916A (zh) * 2006-04-28 2009-09-09 宾夕法尼亚州立大学托管会 规模可调的aav生产方法
CN110520536A (zh) * 2017-02-15 2019-11-29 北卡罗来纳-查佩尔山大学 用于穿过维管结构的基因转移的方法和组合物

Also Published As

Publication number Publication date
IL297577A (en) 2022-12-01
JP2023524291A (ja) 2023-06-09
MX2022013963A (es) 2023-02-22
TW202208631A (zh) 2022-03-01
AR122013A1 (es) 2022-08-03
EP4125977A2 (en) 2023-02-08
US12146151B2 (en) 2024-11-19
US20230151389A1 (en) 2023-05-18
CN116096377A (zh) 2023-05-09
CA3177869A1 (en) 2021-11-11
KR20230029616A (ko) 2023-03-03
US12577586B2 (en) 2026-03-17
US12037598B2 (en) 2024-07-16
US20240076695A1 (en) 2024-03-07
US20240067988A1 (en) 2024-02-29
WO2021226267A3 (en) 2021-12-16
BR112022022644A2 (pt) 2023-01-17
WO2021226267A2 (en) 2021-11-11
JP7756439B2 (ja) 2025-10-20
AU2021268946A1 (en) 2022-12-01
EP4125977A4 (en) 2024-09-25
TWI910162B (zh) 2026-01-01

Similar Documents

Publication Publication Date Title
JP7756439B2 (ja) 異種間適合性アデノ随伴ウイルス組成物およびその使用方法
CN110770346B (zh) 多倍体腺相关病毒载体及其制备和使用方法
JP7303816B2 (ja) Aavベクター
US10385320B2 (en) Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
CN112566923B (zh) 合成嗜肝性腺相关病毒衣壳及其用途
KR102629418B1 (ko) 최적화된 cln1 유전자 및 발현 카세트 및 그의 용도
CN116209768A (zh) 用于通过高变区交换工程化新杂合aav衣壳的方法
KR20240090694A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
WO2024044725A2 (en) Recombinant adeno-associated viruses and uses thereof
EP4185303A1 (en) Dna-binding domain transactivators and uses thereof
CN121532407A (zh) 灵长类动物碳酸酐酶ⅳ结合肽和aav
JP2023545384A (ja) 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス
JP2024515612A (ja) 球脊髄性筋萎縮症(sbma)の治療に有用な組成物
HK40098885A (en) Polyploid adeno-associated virus vectors and methods of making and using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant